Therefore, it seems likely that combining two drugs, Fucoidan and GroA, may have a better inhibitory effect on ErbB-1 receptor activation, and from that activity, a stronger inhibitory effect on cancer cell growth and tumorigenicity. The gene discussed is CXCL1; the disease is cancer.